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ABSTRACT
Objectives To evaluate the association between thyroid
autoantibodies and miscarriage and preterm birth in
women with normal thyroid function. To assess the effect
oftreatmentwithlevothyroxineonpregnancyoutcomesin
this group of women.
Design Systematic review and meta-analysis.
Data sources Medline, Embase, Cochrane Library, and
SCISEARCH (inception-2011) without any language
restrictions. We used a combination of key words to
generate two subsets of citations, one indexing thyroid
autoantibodies and the other indexing the outcomes of
miscarriage and preterm birth.
Study selection Studies that evaluated the association
between thyroid autoantibodies and pregnancy
outcomes were selected in a two stage process. Two
reviewers selected studies that met the predefined and
explicit criteria regarding population, tests, and
outcomes.
Data synthesis Odds ratios from individual studies were
pooled separately for cohort and case-control studies
with the random effects model.
Results 30 articles with 31 studies (19 cohort and 12
case-control) involving 12126 women assessed the
association between thyroid autoantibodies and
miscarriage. Five studies with 12566 women evaluated
the association with preterm birth. Of the 31 studies
evaluatingmiscarriage,28showeda positiveassociation
between thyroid autoantibodies and miscarriage. Meta-
analysis of the cohort studies showed more than tripling
in the odds of miscarriage with the presence of thyroid
autoantibodies(oddsratio3.90,95%confidenceinterval
2.48 to 6.12; P<0.001). For case-control studies the odds
ratio for miscarriage was 1.80, 1.25 to 2.60; P=0.002).
There was a significant doubling in the odds of preterm
birth with the presence of thyroid autoantibodies (2.07,
1.17to3.68;P=0.01).Tworandomisedstudiesevaluated
the effect of treatment with levothyroxine on miscarriage.
Both showed a fall in miscarriage rates, and meta-
analysis showed a significant 52% relative risk reduction
inmiscarriageswithlevothyroxine(relativerisk0.48,0.25
to 0.92; P=0.03). One study reported on the effect of
levothyroxine on the rate of preterm birth, and noted a
69% relative risk reduction (0.31, 0.11 to 0.90).
Conclusion The presence of maternal thyroid
autoantibodies is strongly associated with miscarriage
and preterm delivery. There is evidence that treatment
with levothyroxine can attenuate the risks.
INTRODUCTION
Miscarriage,thelossofapregnancybefore24weeksof
gestation, affects up to one in five women who con-
ceive, making it the commonest complication of
pregnancy.
1 Preterm birth, delivery of a baby between
24 and 37 completed weeks of gestation, occurs in 6-
10%ofpregnancies.
2Upto85%ofneonataldeathsare
attributable to preterm birth (especially those deliv-
ered before 28 weeks). Of those who survive, around
10% have long term disability.
3 The cost of preterm
birth is £93m a year in the United Kingdom.
3 This
includes healthcare costs (including neonatal care),
education, and costs to the parents.
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Fig 1 | Flow chart of study selection in review of association
between thyroid autoantibodies and adverse pregnancy
outcome
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The presence of thyroid autoantibodies is relatively
common in women of reproductive age. In an “unse-
lected” population of women, the prevalence ranges
from 6% to 20%,
45being even higher in women with a
historyofrecurrentpregnancyloss,ataround17-33%,
6-8
andinwomenwithahistoryofsubfertility,ataround10-
31%.
9-11Inthedevelopedworld,thyroidautoimmunity
isthemaincauseofhypothyroidism,whichitselfresults
in poor obstetric outcomes. Even in women with bio-
chemically normal thyroid function, studies have re-
ported an association between the presence of thyroid
autoantibodies, particularly thyroid peroxidase anti-
bodies and adverse pregnancy outcomes, including
miscarriage,pretermbirth,andadverseneurodevelop-
mentalsequelaeinchildren.
1213Theexactmechanisms
of these associations are unknown, though two have
been proposed. Firstly, the presence of thyroid auto-
antibodies in women with normal thyroid function
could be associated with a subtle deficiency in the
availability of thyroid hormones (a fall in circulating
free thyroid hormoneswithin the referencerange) or a
lowercapacityofthethyroidglandtoadequatelyriseto
the demand for augmented synthesis of thyroid hor-
mones required in pregnancy.
14 Given that minor per-
turbations in thyroxine concentrations within the
normalrangecanleadtoanassociationbetweenthyroid
autoantibodiesandadversepregnancyoutcomes,trials
have been conducted to evaluate the effects of supple-
mentationwithlevothyroxineonpregnancyoutcomes
in women with normal thyroid function who tested
positive for thyroid autoantibodies. Secondly, thyroid
autoantibodies might be an indicator of an underlying
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Fig 2 | Association between thyroid autoantibodies and miscarriage in cohort studies
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directadverseeffectonplacentalorfetaldevelopment.
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Given the importance of the potential association
between thyroid autoantibodies and adverse preg-
nancy outcomes, we systematically reviewed and
meta-analysedtheassociationbetweenthyroidautoan-
tibodies and miscarriage and preterm birth. Given the
possibleroleoflevothyroxineinimprovingpregnancy
outcomes, we also reviewed the available randomised
evidence on the effect of treatment with levothyroxine
on pregnancy outcomes.
METHODS
This systematic review was conducted with a prospec-
tive protocol with widely recommended methods.
15
Identification of studies
We searched Medline (1951-2011), Embase (1974-
2011),theCochraneLibrary(2011),andSCISEARCH
(1974-2011) for relevant citations and examined the
reference lists of all known primary and reviewarticles
to identify cited articles not captured by the electronic
searches. Language restrictions were not applied. We
used a combination of MeSH and text words to gener-
ate two subsets of citations, one indexing thyroid auto-
antibodies (“thyroid autoimmune antibodies”, exp
thyroid/ AND exp antibodies, thyroid AND autoim-
mune AND antibodies) and the other indexing
outcomes (“miscarriage”, “abortion”, “pregnancy
loss”, “preterm”, “premature”, “early labo(u)r”, “pret
$”). These subsets were combined with “AND” to gen-
erateasubsetofcitationsrelevanttoourresearchques-
tion.
Study selection and data extraction procedures
Theelectronicsearcheswerescrutinisedandtwoinde-
pendent reviewers (ST and EK) obtained full manu-
scripts of all citations that were likely to meet the
predefined selection criteria. Studies were selected if
they included women with normal thyroid function
who tested positive for thyroid autoantibodies, and
the outcomes included adverse maternal and fetal out-
comes. We excluded articles in which women were
known to have overt biochemical hypothyroidism or
hyperthyroidism.Whendisagreementsoccurred,they
wereresolvedbyconsensusanddiscussionwithathird
reviewer (AC). In cases of duplicate publication, we
selected the most recent and complete versions.
Informationwasextractedfromeachselectedarticle
on study characteristics, quality, and test results. Data
were used to construct 2×2 tables of thyroid autoanti-
bodyresults(testpositiveifconcentrationswereabove
a threshold as defined in the primary study, and test
negative if these were below the threshold) and preg-
nancy outcomes (miscarriage and preterm delivery).
We also extracted data on mean age and serum
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Fig 3 | Association between thyroid autoantibodies and miscarriage in case-control studies
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freethyroxine.Fortherandomisedtrials,we extracted
data on study population, quality of the methods,
details of the interventions, and outcomes.
Assessment of quality of methods
We used the Newcastle-Ottawa scale
16 to assess metho-
dological quality of the selected studies, with the com-
ponents of study design that are related to internal
validity. Information on adequacy of definition of
casesorcohorts,representativenessofthesample,selec-
tion and evaluation of controls, comparability, ascer-
tainment of exposure, and outcome were evaluated for
cohortandcase-controlstudies.
16Thestudywasconsid-
eredtohavelowriskofbiasifitscoredamaximumof4
for selection, 2 for comparability, and 3 for assessment
of outcome or ascertainment of exposure. Any study
that scored 1 or zero for selection or zero for compar-
ability or for outcome assessment was categorised as
havingahighriskofbias.Studiesthatscoredinbetween
were rated as having medium risk of bias.
We assessed quality of randomised trials evaluating
the effectiveness of levothyroxine according to appro-
priate randomisation, concealment of allocation,
blinding, analysis by intention to treat, and follow-up
rates. A quality score for the randomised trials was
given on Jadad’s scale.
17
Data synthesis
Odds ratios from individual studies were pooled sepa-
rately for the cohort and case-control studies with the
random effects model. Heterogeneity of treatment
effects was evaluated graphically with forest plots and
statistically with χ
2 and I
2 tests. We generated the
pooled mean difference in age and weighted mean dif-
ference in serum thyroid stimulating hormone
between groups with positive and negative results for
thyroid autoantibodies. All analyses were performed
with Stata 10.0 and Revman 5 statistical software.
1819
RESULTS
Figure 1 summarises the processes of literature identi-
fication and selection of studies evaluating the relation
between thyroid autoantibodies and adverse preg-
nancy outcomes. From the 389 citations identified
fromelectronicandhandsearches,weincluded30pri-
mary articles with 36 studies (31 for miscarriage and
five for preterm birth) in the systematic review.
Thyroid autoantibodies and miscarriage
Thirty one studies (12126 women)
6-1220-41 evaluated
the association between thyroid autoantibodies and
miscarriage. Nineteen studies were cohort studies,
and 12 were case-control studies. Thirteen studies
(three cohort, 10 case-control) evaluated the associa-
tioninwomenwithrecurrentmiscarriage,ninestudies
(sevencohort,twocase-control)inwomenwithsubfer-
tility and nine cohort studies in unselected or other
populations. The studies were judged to have low risk
of bias for assessment of outcome (19/19 cohort stu-
dies) and ascertainment of exposure (12/12 case-con-
trol studies) on the Newcastle-Ottawa scale.
16 Nearly
half the cohort studies (9/19) had low selection bias
and the others (10/19) had medium selection bias. All
the case-control studies had medium selection bias.
Eight of the 19 (42%) cohort studies had established
good comparability of the groups compared with
16% (2/12) of the case-control studies.
Appendix1onbmj.comprovidesdetailsofthechar-
acteristics of the women in the included studies. All
studies tested for thyroid peroxidase antibodies. Stu-
diesvariedinthefrequencyandtimingoftheautoanti-
bodytesting,rangingfromtestingbeforepregnancy,in
earlypregnancy,andafterdeliveryormiscarriage.The
commonest threshold concentration of thyroid perox-
idasefora diagnosisofpositivethyroidautoantibodies
was >100 U/ml. The various thresholds used to define
positivity for thyroid autoantibodies are in appendix 1
on bmj.com.
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Fig 4 | Comparison of age between women postive and negative for thyroid autoantibodies in included studies
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control) studies showed a positive association between
thyroid autoantibodies and spontaneous miscarriage.
Meta-analysis of the cohort studies found more than
tripling in the odds of miscarriage in the presence of
thyroid autoantibodies (odds ratio 3.90, 95% confi-
dence interval 2.48 to 6.12; P<0.001) (fig 2). The
odds of miscarriage with thyroid autoantibodies was
increased for women with recurrent miscarriages
(4.22, 0.97 to 18.44; P=0.06), women with subfertility
(3.15, 2.23 to 4.44; P<0.001), and unselected or other
populations (4.28, 2.06 to 8.92; P<0.001). There was
significant unexplained heterogeneity for studies in
women with recurrent miscarriage (I
2=75%) and the
unselected population (I
2=89%). There was no evi-
dence of heterogeneity for studies in women with sub-
fertility (I
2=0%) (fig 2).
Meta-analysis of the 12 case-control studies also
showed an increase in the odds of miscarriage in
womenwithnormalthyroidfunctionandthyroidauto-
antibodies (1.80, 1.25 to 2.60; P=0.002) (fig 3). The
odds of miscarriage was increased in two subgroups:
women with recurrent miscarriage (1.86, 1.18 to 2.94;
P=0.008) and women with subfertility (1.50, 0.99 to
2.26; P=0.05).
As increasing maternal age is an “independent” risk
factor for miscarriage,
42 we examined the difference in
the mean age of women who were positive or negative
for thyroid autoantibodies through a meta-analysis of
the 10 studies that reported age. There was no signifi-
cantdifferencebetweenthegroups(weightedmeandif-
ference 0.87 years, −0.06 to 1.80 years; P=0.07, fig 4).
Toexplorethehypothesisthatwomenwhoareposi-
tiveforthyroidautoantibodieshaverelativehypothyr-
oidism, we meta-analysed the serum thyroid
stimulating hormone concentrations in six studies.
The weighted mean difference for thyroid stimulating
hormone was significantly higher in the thyroid auto-
antibody positive group compared with the negative
group by 0.51 mIU/L (95% confidence interval 0.14
to 0.88; P=0.007), giving credibility to this hypothesis
(fig 5). There were insufficient data on serum free
thyroxine(fT4)andfreetriiodothyronine(T3)concen-
trations for meta-analysis.
Thyroid autoantibodies and preterm birth
Five studies
28-304344 including a total of 12566 women
evaluated the association between thyroid autoantibo-
diesandpretermbirth.Allwerecohortstudiesandhad
low risk of bias for selection and outcome assessment
on the Newcastle-Ottawa scale.
16 Three studies were
judged to have medium risk of bias and two as high
risk of bias for comparability of cohorts. All showed a
positive association between the presence of thyroid
autoantibodies and preterm births. Meta-analysis
showed an increase in the odds of preterm birth in
the presence of thyroid autoantibodies (2.07, 1.17 to
3.68; P=0.01) (fig 6).
Effect of levothyroxine treatment on pregnancy outcomes
Two randomised studies, including a total of 187
women, evaluated the effect of levothyroxine treat-
ment on pregnancy outcomes.
2344 Both studies were
in women with normal thyroid function with thyroid
autoantibodies. One study was in unselected women
44
and the other in women scheduled to have in vitro fer-
tilisationtreatment.
23Oneusedlevothyroxineatadose
of 1 µg/kg/day,
23 and the other used a titrated dose,
with a mean levothyroxine dose of 49.7 µg/day (SD
14 µg) in the treatment group.
44 The Jadad score
17 for
quality of the studies was 5/5 and 3/5. Both studies
showed a reduction in miscarriage rates (36% and
75% relative reductions), and when the results were
pooled, there was a significant 52% relative risk reduc-
tion in miscarriages with levothyroxine (0.48, 0.25 to
0.92;P=0.03)(fig7).Oneofthetwostudiesreportedon
preterm birth
44; this study (n=115) found a 69% rela-
tive risk reduction in preterm births with levothyrox-
ine (0.31, 0.11 to 0.90).
DISCUSSION
Association of thyroid autoantibodies with adverse
pregnancy outcomes
Our systematic review and meta-analysis of the pub-
lished literature showed that in women with normal
  Bagis 2001
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Fig 5 | Comparison of serum thyroid stimulating hormone (TSH) concentration between women positive and negative for thyroid
autoantibodies in included studies
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BMJ | ONLINE FIRST | bmj.com page 5 of 8thyroid function, there is a strong association between
thepresenceofthyroidautoantibodiesandpoorobste-
tric outcomes, for both miscarriage and preterm birth.
The odds of miscarriage more than tripled and that of
preterm birth doubled in women with thyroid autoan-
tibodies.
Giventhehighprevalenceofthyroidautoantibodies
inwomenofreproductiveagegroup,theseincreasesin
miscarriage and preterm birth are clinically highly
relevant at the individual and population level. We
showed that the increase in miscarriage rates in
women positive for thyroid autoantibodies could not
be accounted for by confounding factors such as a dif-
ference in age. Our review of the effectiveness of treat-
ment with levothyroxine has provided preliminary
evidenceonits efficacy in reducingthe rates ofmiscar-
riages and preterm births.
Fivereviewshaveexaminedtheassociationbetween
thyroid autoantibodies and miscarriage,
45144546 and
one has examined the association with preterm
birth.
47 Several new studies have emerged since these
reviews were completed, however, and the existing
reviews have used limited meta-analytical methods,
necessitating our review.
Pathogenesis of adverse pregnancy outcomes with thyroid
autoantibodies
The frequentpresence ofthyroid autoantibodies in sev-
eral non-thyroidal autoimmune diseases supports a
hypothesis of global immune dysfunction being rele-
vant to these clinical outcomes.
48 There is evidence
thatthereisanalterationincytokineexpressionbyper-
ipheral T lymphocytes in women positive for thyroid
antibodies outside of pregnancy.
49 Pregnancy is an
inflammatoryprocessinvolvingashiftintheregulation
ofcytokinenetworkswithinthelocalplacental-decidual
environment.
50 Dysregulation of local inflammatory
processes can be associated with miscarriage and pre-
mature delivery.
51 The presence of thyroid autoantibo-
dies can reflect a generalised activation of the immune
system and specifically a dysregulated activity of the
immunesystem atthe fetal-maternal interface.Thyroid
hormones can directly influence angiogenic growth
factor and cytokine production
5253 as well as tropho-
blast proliferation, survival, and invasion.
5455 Further-
more, the presence of thyroid autoantibodies might be
a marker of underlying subtle alteration in thyroid
reserve. A reduction in the functional reserve of the
thyroid gland associated with reduced adaptation to
the physiological changes of pregnancy could contri-
bute to minor changes in circulating thyroid hormone
concentrations within the reference range.
56 The
increaseinthyroidstimulatinghormoneconcentrations
in euthyroid women with thyroid autoantibodies sup-
ports this hypothesis. There were insufficient data to
identify any differences in the concentrations of triio-
dothyronine(T3)betweenthetwogroups.Wepostulate
that treatment with levothyroxine might correct any
relative deficiency of thyroid hormones and impact on
both systemic immune regulation and the local placen-
tal-decidual environment.
Clinical implications of the findings
The prevalence of the thyroid autoantibodies in the
included studies varied between 5.4% and 31%. The
miscarriage rates ranged from 2.4% to 42.9%. The
association between thyroid autoantibodies and mis-
carriage was consistently strong across varying rates
of thyroid autoantibodies and miscarriages. The indi-
vidual studies used various assays for thyroid peroxi-
dase antibodies, each with different detection limits
and thresholds for test positivity, which were usually
predetermined by the assay manufacturer. The effect
size does not seem to be related to the threshold con-
centrations of thyroid peroxidase antibodies.
Although28ofthe31miscarriagestudiesandallfive
preterm studies showed a positive association, there
was still unexplained heterogeneity in the meta-ana-
lyses for both miscarriage and preterm birth. The clin-
ical heterogeneity between the studies on the
population, test assay platforms, and thresholds used
and the quality features of the studies are likely to
have contributed to the statistical heterogeneity
observed.
The strength of inference on the effectiveness of
levothyroxine is weakened by the small number of
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  Negro 2006
44
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Test for heterogeneity: τ2=0.31, χ
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Fig 6 | Association between thyroid autoantibodies and preterm births
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page 6 of 8 BMJ | ONLINE FIRST | bmj.comstudies. There have been only two small randomised
trialsinvolvingatotalof187women.Oneofthemwas
not placebo controlled. To obtain a definitive answer
on the role of levothyroxine in reducing miscarriages
and preterm births a large placebo controlled rando-
mised trial is needed with live births as the primary
outcome. The two randomised studies included in the
review did not find any safety concerns for the mother
or the baby; specifically there were no instances of
hyperthyroidism (resulting from overtreatment with
levothyroxine). As the randomised trials were small
and the follow-up was only to the end of pregnancy,
however, these trials were not suitable for assessing
rare or long term adverse events. Furthermore, the
two trials on this topic have been conducted in the
same research unit, with possible implications to the
generalisability of the findings.
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